Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?

被引：1
|
作者：
Samson, M. [1 ,2 ,3 ]
Bonnotte, B. [1 ,2 ,3 ]
机构：
[1] CHU Dijon Bourgogne, Serv Med Interne, 2 Blvd Mal de Lattre de Tassigny, F-21000 Dijon, France
[2] CHU Dijon Bourgogne, Immunol Clin, 2 Blvd Mal de Lattre de Tassigny, F-21000 Dijon, France
[3] Univ Bourgogne Franche Comte, FHU Increase, Inserm U1098, F-21000 Dijon, France
来源：
REVUE DE MEDECINE INTERNE | 2018年 / 39卷 / 02期
关键词：
Giant cell arteritis; Treatment; Tocilizumab; LARGE-VESSEL VASCULITIS; TAKAYASU ARTERITIS; DOUBLE-BLIND; THERAPY; TRIAL; ABATACEPT;
D O I：
10.1016/j.revmed.2017.11.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 77
页数：3
相关论文
共 50 条
  • [41] Vision loss in patients with giant cell arteritis treated with tocilizumab
    Amsler, Jennifer
    Kysela, Iveta
    Tappeiner, Christoph
    Seitz, Luca
    Christ, Lisa
    Scholz, Godehard
    Stalder, Odile
    Kollert, Florian
    Reichenbach, Stephan
    Villiger, Peter M.
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [42] Tocilizumab for relapsing and remitting giant cell arteritis: a case series
    Pratyasha Saha
    Denesh Srikantharajah
    Arvind Kaul
    Nidhi Sofat
    Journal of Medical Case Reports, 16
  • [43] Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
    Ohta, Ryuichi
    Nishikura, Nozomi
    Ikeda, Hirotaka
    Sano, Chiaki
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [44] Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
    Hara, Kazusato
    Umeda, Masataka
    Segawa, Keiko
    Akagi, Midori
    Endo, Yushiro
    Koga, Tomohiro
    Kawashiri, Shin-Ya
    Ichinose, Kunihiro
    Nakamura, Hideki
    Maeda, Takahiro
    Kawakami, Atsushi
    INTERNAL MEDICINE, 2022, 61 (08) : 1265 - 1270
  • [45] Vision loss in patients with giant cell arteritis treated with tocilizumab
    Jennifer Amsler
    Iveta Kysela
    Christoph Tappeiner
    Luca Seitz
    Lisa Christ
    Godehard Scholz
    Odile Stalder
    Florian Kollert
    Stephan Reichenbach
    Peter M. Villiger
    Arthritis Research & Therapy, 23
  • [46] Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients
    Regola, Francesca
    Cerudelli, Elisabetta
    Bosio, Giovanni
    Andreoli, Laura
    Tincani, Angela
    Franceschini, Franco
    Toniati, Paola
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2020, 4 (02)
  • [47] Actual Treatment Options for Giant Cell Arteritis
    Moosig, Frank
    Schmalzing, Marc
    Aries, Peer Malte
    Henes, Joerg
    Lamprecht, Peter
    Rech, Juergen
    Witte, Torsten
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (09) : 595 - 600
  • [48] The Treatment of Giant Cell Arteritis
    Jivraj, Imran
    Tamhankar, Madhura
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2017, 19 (01)
  • [49] Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis
    Dumont, Anael
    Parienti, Jean-Jacques
    Delmas, Claire
    Boutemy, Jonathan
    Maigne, Gwenola
    Silva, Nicolas Martin
    Sultan, Audrey
    Planchard, Gaetane
    Aouba, Achille
    de Boysson, Hubert
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (01) : 108 - 116
  • [50] Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
    Cho, Young Min
    El Khoury, Lara
    Paramo, Jonathan
    Horowitz, Diane Michelle
    Li, Jian Yi
    Kello, Nina
    BMC MUSCULOSKELETAL DISORDERS, 2023, 24 (01)
12345